Every quarter, this API maker’s earnings call turns into the same tug of war. Analysts ask how much of the growth is custom synthesis and how much is just generics catching a good quarter, and management gives an answer that’s honest but frustratingly vague. Lately, though, one side of that mix has climbed to a level it hasn’t touched in over a year, and that’s worth digging into properly instead of just taking the headline number at face value.
Divis Laboratories Ltd is trading at ₹9,444.50, up ₹100.5 or about 1.08% from the previous close of ₹9,344. It’s sitting close to its 52-week high of ₹10,000, and well above the ₹5,637.50 low it touched a year ago.
So the stock’s roughly 65% off its yearly bottom. Market cap stands at ₹2,50,643 crore, with the consolidated price-to-earnings ratio sitting at nearly 85 times, a valuation that’s stayed above 50 for four straight quarters now.
What The Filings Actually Show
Custom synthesis (CS) is the business of manufacturing active ingredients and intermediates on contract for global innovator pharma companies, essentially, the company makes the complex chemistry these drugmakers need but don’t want to build capacity for themselves, under long-term customer relationships. It’s generally seen as stickier and higher-margin than plain generic API manufacturing, which is why analysts track this mix so closely.
Go back to the December 2024 quarter and custom synthesis (CS) made up 53% of consolidated revenue, generics the rest. It then dipped to 51% in the March 2025 quarter, before climbing again: 53% in June 2025, 56% in September, and 57% by December 2025. The company hasn’t disclosed a standalone quarterly mix for the January-March 2026 quarter, so there’s a gap there.
Also Read: 2 Tata Group Stocks to Buy With an Upside Potential of Up to 36%; Do You Hold Any?
What’s confirmed is the June 2026 quarter, where CS jumped to 60%, its highest print across every quarter on record here. So the honest read is: this isn’t a clean upward line, CS actually slipped a couple of points in early 2025 before resuming its climb, but the direction over the last five confirmed quarters is unmistakably toward custom synthesis, and the current quarter is a genuine high point, not just noise.
The Bigger Picture They’re Betting On
Custom synthesis is Divi’s term for its contract manufacturing business, making active ingredients and intermediates for global innovator pharma companies, and it sits within the broader global CDMO industry, valued at roughly USD 150 billion in 2024 and projected to nearly double to USD 290-300 billion by the early 2030s. Within that opportunity, the company’s stated approach is to keep expanding its custom synthesis participation across development, validation and commercial stages, and deepen backward integration to strengthen supply reliability for long-term customer programmes.
The Margin Number Needs An Asterisk
Gross margin for the June quarter came in close to 68%, well above the roughly 60% the company’s been running at over a full year. On paper that looks like a big jump. Except a big chunk of it is tied to a nearly ₹500 crore swing in inventory, way above the usual ₹50-100 crore range, driven by a decision to stock raw materials three months ahead rather than just-in-time.
Management itself flagged this as a factor pushing up the reported margin this quarter, rather than a genuine structural improvement. Solvent costs, tied largely to ongoing disruption in West Asia, have also been running high, and some of that’s simply been passed through to customers rather than absorbed.
Kakinada Is Still A Slow Build
Divi’s Unit 3 facility at Kakinada is doing a lot of the quiet heavy lifting here, freeing up capacity at the older units by taking on pre-chemistry and backward-integrated work. Three major capex projects tied to long-term customer contracts are now roughly 70% capitalised, with capital work-in-progress at over ₹2,000 crore as of June 2026.
But getting Kakinada itself fully regulatory-approved is a multi-year process, management has pointed out FDA clearance alone can take a year or two once a new site starts producing, so the commercial payoff from this site is still some way out even though the groundwork is largely done.
Peptides And Contrast Media Are The Next Leg
Peptides are short amino-acid chains used in drugs like GLP-1 weight-loss treatments, and manufacturing them at scale needs deep backward integration, exactly the edge the company’s building from raw materials to fragments, backed by more solid-phase synthesis capacity.
Contrast media are the dyes injected before MRI and CT scans to sharpen imaging. Iodine and gadolinium-based agents need tightly regulated manufacturing, and this company supplies innovator pharma here too. Long-term contracts with two customers are underway, one already shipping commercially, the second expected in coming months. Worth flagging: no molecule names or volumes are company-disclosed, anything specific elsewhere is analyst estimation, not confirmed fact.
Bottom Line
The custom synthesis number is genuinely improving, and the current quarter is its best print on record, but the path there wasn’t a straight line, it dipped once along the way before resuming its climb. This quarter’s margin strength also owes more to an inventory stocking decision than to any structural cost advantage kicking in yet.
Also Read: Swastika Infra IPO: Opens At ₹175–185 Price Band; Order Book Stands at ₹2,036 Cr
Kakinada, peptides and contrast media all look like real medium-term opportunities, just not ones that show up cleanly in any single quarter’s numbers. At close to 87 times earnings, the stock’s already assuming a lot of this plays out on schedule.
About the Company
Divis Laboratories Ltd. is one of the world’s larger manufacturers of active pharmaceutical ingredients, split across a generics business, a custom synthesis arm that manufactures for global innovator pharma companies, and a smaller nutraceuticals segment. It exports roughly 90% of what it makes, with Europe and North America together accounting for around three-quarters of that. It also runs peptide synthesis and contrast media manufacturing as newer growth bets alongside its core API business.